Methods of treating cancer using androgen receptor antagonists
The present disclosure generally relates to cancer and methods of treating and diagnosing cancer.
1 . A method of sensitizing a cancer cell in a subject to an anti-cancer agent, comprising administering to the subject an androgen receptor antagonist, wherein the cell is a breast cancer cell, wherein the anti-cancer agent is docetaxel, paclitaxel, or doxorubicin, and wherein the androgen receptor antagonist is seviteronel.
2 . The method according to claim 1 wherein the cancer cell is a poorly tumourigenic cell or a highly tumourigenic cell.
3 . The method according to claim 1 , wherein the cancer cell is a CD44 Lo cell.
4 . The method according to claim 2 , wherein the method comprises impeding or preventing the development of resistance to the anti-cancer agent.
5 . The method according to claim 1 , wherein the cancer cell is a CD44 Hi cell.
6 . The method according to claim 5 , wherein the method comprises inhibiting proliferation of the CD44 Hi cell or increasing sensitivity of the CD44 Hi cell to an anti-cancer agent.
7 . The method according to claim 1 , wherein the method comprises determining the level of expression and/or activity of the androgen receptor and/or ZEB1 in the cell.
8 . The method according to claim 1 , wherein the method comprises determining the level of expression and/or activity of the androgen receptor and/or ZEB1 in the cytoplasm of the cell.
9 . A method of inhibiting the development of resistance to an anti-cancer agent in a cancer cell in a subject, the method comprising: determining the level of expression and/or activity of the androgen receptor and/or ZEB1 in the cancer cell; and administering to the subject an androgen receptor antagonist if the level of expression and/or activity of the androgen receptor and/or ZEB1 is low, wherein the cell is a breast cancer cell, wherein the anti-cancer agent is docetaxel, paclitaxel, or doxorubicin, and wherein the androgen receptor antagonist is seviteronel.
10 . A method of inhibiting the proliferation of a cancer cell in a subject, the method comprising: determining the level of expression and/or activity of the androgen receptor and/or ZEB1 in the cancer cell; and administering to the subject an androgen receptor antagonist if the level of expression and/or activity of the androgen receptor and/or ZEB1 is high, wherein the cell is a breast cancer cell, wherein the anti-cancer agent is docetaxel, paclitaxel, or doxorubicin, and wherein the androgen receptor antagonist is seviteronel.
11 . The method according to claim 9 , wherein the level of expression and/or activity of the androgen receptor and/or ZEB1 is determined in the cytoplasm of the cell.